Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. · 2019
Read Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. by Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6889302.txt.
Description
Sahin and co-authors review checkpoint drugs for a distinct bowel cancer type, in the British Journal of Cancer. Some colorectal cancers cannot repair DNA mismatches. Their tumours carry many mutations and draw in immune cells. Such MSI-high cancers respond to immune checkpoint inhibitors in a lasting way for many patients. Response rates, though, sit between 30 and 50 percent.
The rest resist from the start, and some responders later relapse. The review covers the trials that proved the benefit, then dissects resistance. Tumours can lose the machinery that displays antigens, including through faults in the beta-2 microglobulin gene. Broken interferon signalling through Janus kinases is another escape. The authors map trials now testing combinations.
Catalog record
| CREATOR | Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |